| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urokinase-Type Plasminogen Activator | 71 | 2022 | 326 | 7.090 |
Why?
|
| Fibrinolysis | 46 | 2019 | 332 | 4.250 |
Why?
|
| Tissue Plasminogen Activator | 31 | 2022 | 1190 | 2.820 |
Why?
|
| Plasminogen Activators | 29 | 2017 | 199 | 2.400 |
Why?
|
| Thrombolytic Therapy | 16 | 2022 | 2108 | 2.110 |
Why?
|
| Fibrin | 39 | 2017 | 505 | 2.080 |
Why?
|
| Plasminogen | 27 | 2009 | 146 | 1.930 |
Why?
|
| Fibrinolytic Agents | 23 | 2022 | 2167 | 1.300 |
Why?
|
| Enzyme Precursors | 14 | 1996 | 174 | 1.120 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 14 | 2017 | 418 | 0.900 |
Why?
|
| Recombinant Proteins | 33 | 2022 | 6538 | 0.900 |
Why?
|
| Streptokinase | 14 | 2019 | 187 | 0.900 |
Why?
|
| Fibrinolysin | 18 | 2009 | 131 | 0.670 |
Why?
|
| Thrombin | 21 | 2017 | 593 | 0.660 |
Why?
|
| Fibrinogen | 38 | 2017 | 887 | 0.620 |
Why?
|
| Thrombosis | 12 | 2017 | 3051 | 0.610 |
Why?
|
| Complement C1 Inactivator Proteins | 2 | 2009 | 92 | 0.610 |
Why?
|
| Myocardial Infarction | 12 | 2019 | 11890 | 0.570 |
Why?
|
| Factor XIII | 1 | 2017 | 59 | 0.560 |
Why?
|
| Antifibrinolytic Agents | 1 | 2017 | 292 | 0.440 |
Why?
|
| Mutant Proteins | 1 | 2015 | 492 | 0.430 |
Why?
|
| Hemostasis | 3 | 2006 | 468 | 0.410 |
Why?
|
| Blood Coagulation | 13 | 2016 | 1157 | 0.380 |
Why?
|
| Thrombophlebitis | 13 | 1994 | 289 | 0.380 |
Why?
|
| Neovascularization, Physiologic | 3 | 2014 | 1336 | 0.370 |
Why?
|
| Fibronectins | 1 | 2014 | 722 | 0.370 |
Why?
|
| Lipoprotein(a) | 4 | 1998 | 499 | 0.350 |
Why?
|
| Blood Platelets | 19 | 2002 | 2519 | 0.310 |
Why?
|
| Drug Synergism | 9 | 2017 | 1752 | 0.310 |
Why?
|
| Lysine | 6 | 2002 | 1001 | 0.270 |
Why?
|
| Antibodies | 1 | 2014 | 2421 | 0.270 |
Why?
|
| Serpins | 1 | 2007 | 247 | 0.250 |
Why?
|
| Stroke | 4 | 2015 | 9952 | 0.250 |
Why?
|
| Kinetics | 18 | 2009 | 6377 | 0.250 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 16 | 2007 | 1744 | 0.240 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 2049 | 0.230 |
Why?
|
| Mutagenesis, Site-Directed | 9 | 2009 | 1693 | 0.230 |
Why?
|
| Hemorrhage | 7 | 2019 | 3599 | 0.230 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 2640 | 0.230 |
Why?
|
| Azetidines | 1 | 2005 | 141 | 0.230 |
Why?
|
| Disseminated Intravascular Coagulation | 10 | 1979 | 187 | 0.230 |
Why?
|
| Enzyme Activation | 15 | 2007 | 3602 | 0.220 |
Why?
|
| Isoflurophate | 4 | 1998 | 28 | 0.220 |
Why?
|
| Prodrugs | 1 | 2005 | 259 | 0.210 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 2526 | 0.210 |
Why?
|
| Endothelium, Vascular | 6 | 2006 | 4434 | 0.210 |
Why?
|
| Endovascular Procedures | 1 | 2015 | 2134 | 0.200 |
Why?
|
| Brain Ischemia | 1 | 2015 | 3127 | 0.200 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2008 | 1880 | 0.200 |
Why?
|
| Drug Therapy, Combination | 7 | 2019 | 6498 | 0.190 |
Why?
|
| Prekallikrein | 3 | 1995 | 11 | 0.170 |
Why?
|
| Commerce | 1 | 2005 | 605 | 0.170 |
Why?
|
| Heparin | 18 | 1994 | 1652 | 0.170 |
Why?
|
| Dogs | 5 | 2011 | 3841 | 0.170 |
Why?
|
| Blood Coagulation Tests | 18 | 1988 | 270 | 0.170 |
Why?
|
| Complement C1 Inhibitor Protein | 2 | 2011 | 96 | 0.160 |
Why?
|
| Protamines | 12 | 1976 | 111 | 0.160 |
Why?
|
| Humans | 122 | 2022 | 760613 | 0.150 |
Why?
|
| Health Care Rationing | 2 | 1998 | 435 | 0.150 |
Why?
|
| Structure-Activity Relationship | 4 | 2016 | 3085 | 0.130 |
Why?
|
| Resource Allocation | 1 | 1998 | 349 | 0.130 |
Why?
|
| Protein Binding | 9 | 2014 | 9335 | 0.130 |
Why?
|
| Dipyridamole | 5 | 1983 | 143 | 0.130 |
Why?
|
| Rabbits | 27 | 2011 | 4773 | 0.130 |
Why?
|
| Arterial Occlusive Diseases | 2 | 1998 | 752 | 0.120 |
Why?
|
| HT29 Cells | 1 | 2014 | 190 | 0.120 |
Why?
|
| alpha-2-Antiplasmin | 2 | 2009 | 13 | 0.120 |
Why?
|
| DNA, Single-Stranded | 1 | 1996 | 360 | 0.120 |
Why?
|
| Truth Disclosure | 1 | 1998 | 432 | 0.120 |
Why?
|
| Leg | 3 | 1998 | 1091 | 0.120 |
Why?
|
| Platelet Activation | 1 | 1997 | 660 | 0.110 |
Why?
|
| Diatomaceous Earth | 2 | 1990 | 5 | 0.110 |
Why?
|
| Monocytes | 3 | 2001 | 2575 | 0.110 |
Why?
|
| Ethics, Medical | 1 | 1998 | 783 | 0.110 |
Why?
|
| Managed Care Programs | 1 | 1998 | 939 | 0.110 |
Why?
|
| Bacteriophages | 1 | 1996 | 372 | 0.110 |
Why?
|
| Coronary Thrombosis | 3 | 1993 | 486 | 0.100 |
Why?
|
| Disclosure | 1 | 1998 | 738 | 0.100 |
Why?
|
| Plasminogen Inactivators | 3 | 1988 | 37 | 0.100 |
Why?
|
| Anticoagulants | 5 | 2005 | 4897 | 0.100 |
Why?
|
| Enzyme Stability | 3 | 2006 | 220 | 0.100 |
Why?
|
| Cyclic AMP | 1 | 1995 | 1456 | 0.100 |
Why?
|
| Serine Endopeptidases | 1 | 1996 | 1021 | 0.100 |
Why?
|
| DNA, Bacterial | 1 | 1996 | 1456 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 1998 | 1501 | 0.090 |
Why?
|
| Umbilical Veins | 4 | 2006 | 426 | 0.090 |
Why?
|
| Molecular Weight | 12 | 1988 | 2186 | 0.090 |
Why?
|
| Animals | 41 | 2019 | 167960 | 0.090 |
Why?
|
| Receptors, Cell Surface | 5 | 2007 | 2825 | 0.090 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 1837 | 0.090 |
Why?
|
| Cell Adhesion | 2 | 1996 | 3094 | 0.090 |
Why?
|
| Alanine | 1 | 1992 | 606 | 0.080 |
Why?
|
| DNA, Viral | 1 | 1996 | 2194 | 0.080 |
Why?
|
| Mice, SCID | 1 | 2014 | 2627 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 1994 | 782 | 0.080 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 4 | 2007 | 75 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2014 | 1895 | 0.080 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2009 | 278 | 0.080 |
Why?
|
| Epitopes | 1 | 2014 | 2503 | 0.080 |
Why?
|
| Thromboembolism | 9 | 1995 | 1016 | 0.070 |
Why?
|
| Lipoproteins, HDL | 2 | 1982 | 667 | 0.070 |
Why?
|
| Shwartzman Phenomenon | 3 | 1976 | 9 | 0.070 |
Why?
|
| Carboxypeptidase B | 3 | 1993 | 6 | 0.070 |
Why?
|
| Peptide Fragments | 6 | 2002 | 5132 | 0.070 |
Why?
|
| Endotoxins | 7 | 1976 | 521 | 0.070 |
Why?
|
| Catalysis | 5 | 2000 | 775 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2005 | 5325 | 0.070 |
Why?
|
| Treatment Outcome | 6 | 2022 | 64981 | 0.070 |
Why?
|
| Coronary Disease | 4 | 1994 | 5991 | 0.070 |
Why?
|
| Physical Exertion | 3 | 1983 | 662 | 0.070 |
Why?
|
| Carboxypeptidases | 3 | 1993 | 155 | 0.070 |
Why?
|
| Time Factors | 15 | 2014 | 40139 | 0.070 |
Why?
|
| Transfection | 1 | 2014 | 5781 | 0.070 |
Why?
|
| Kininogens | 2 | 1996 | 15 | 0.070 |
Why?
|
| Cell Membrane | 1 | 1996 | 3682 | 0.070 |
Why?
|
| Pulmonary Embolism | 11 | 1976 | 2543 | 0.070 |
Why?
|
| Intracellular Membranes | 1 | 2007 | 389 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 3583 | 0.070 |
Why?
|
| Substrate Specificity | 4 | 1997 | 1792 | 0.060 |
Why?
|
| RNA Interference | 1 | 2014 | 2846 | 0.060 |
Why?
|
| Models, Biological | 3 | 2017 | 9468 | 0.060 |
Why?
|
| Femoral Vein | 3 | 2002 | 153 | 0.060 |
Why?
|
| Hydrolysis | 3 | 1998 | 665 | 0.060 |
Why?
|
| Femoral Artery | 3 | 2006 | 831 | 0.060 |
Why?
|
| Plethysmography, Impedance | 2 | 1980 | 42 | 0.060 |
Why?
|
| Factor XIIa | 2 | 1994 | 14 | 0.060 |
Why?
|
| Benzylamines | 1 | 2005 | 248 | 0.060 |
Why?
|
| Mutation | 3 | 2011 | 29957 | 0.060 |
Why?
|
| Amino Acid Sequence | 6 | 1995 | 13451 | 0.060 |
Why?
|
| Stem Cells | 2 | 2007 | 3524 | 0.060 |
Why?
|
| Aspirin | 5 | 1983 | 3364 | 0.050 |
Why?
|
| Binding Sites | 4 | 2002 | 6048 | 0.050 |
Why?
|
| Blood Coagulation Disorders | 3 | 1976 | 349 | 0.050 |
Why?
|
| Chemical Precipitation | 3 | 1996 | 176 | 0.050 |
Why?
|
| Bleeding Time | 1 | 2002 | 84 | 0.050 |
Why?
|
| Epoprostenol | 1 | 1983 | 248 | 0.050 |
Why?
|
| Prostaglandins | 1 | 1983 | 398 | 0.050 |
Why?
|
| Drug Stability | 1 | 2002 | 290 | 0.050 |
Why?
|
| Kidney | 6 | 1992 | 7064 | 0.050 |
Why?
|
| Mannose-Binding Lectins | 1 | 2001 | 96 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1996 | 2753 | 0.050 |
Why?
|
| Sequence Alignment | 2 | 1996 | 2176 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2002 | 1737 | 0.050 |
Why?
|
| Factor XII | 3 | 1996 | 19 | 0.040 |
Why?
|
| Cell Line | 7 | 2007 | 15620 | 0.040 |
Why?
|
| Endopeptidases | 3 | 1983 | 772 | 0.040 |
Why?
|
| Leukocyte Count | 4 | 1976 | 1599 | 0.040 |
Why?
|
| Escherichia coli | 6 | 1997 | 4219 | 0.040 |
Why?
|
| Propanolamines | 2 | 1979 | 162 | 0.040 |
Why?
|
| Disease Models, Animal | 5 | 2006 | 18137 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 629 | 0.040 |
Why?
|
| Blood Cell Count | 7 | 1976 | 398 | 0.040 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 1978 | 46 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2002 | 1347 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2001 | 476 | 0.040 |
Why?
|
| Leukocytes | 3 | 1976 | 2027 | 0.040 |
Why?
|
| Budd-Chiari Syndrome | 1 | 1978 | 24 | 0.040 |
Why?
|
| Plasma | 1 | 2002 | 584 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 1998 | 18955 | 0.040 |
Why?
|
| Iodine Radioisotopes | 7 | 1986 | 1032 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 1 | 1998 | 182 | 0.040 |
Why?
|
| National Health Insurance, United States | 1 | 1998 | 100 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 1982 | 1064 | 0.040 |
Why?
|
| Macromolecular Substances | 2 | 1993 | 1433 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 3 | 2002 | 3800 | 0.040 |
Why?
|
| Hemostasis, Surgical | 1 | 1978 | 129 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1722 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1993 | 2502 | 0.040 |
Why?
|
| Nucleic Acid Renaturation | 1 | 1996 | 11 | 0.030 |
Why?
|
| Molecular Sequence Data | 4 | 1995 | 17624 | 0.030 |
Why?
|
| Blood Coagulation Factors | 2 | 1996 | 366 | 0.030 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1980 | 866 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 844 | 0.030 |
Why?
|
| Solubility | 5 | 1976 | 1088 | 0.030 |
Why?
|
| Oxidation-Reduction | 2 | 1998 | 2222 | 0.030 |
Why?
|
| Leukopenia | 2 | 1976 | 212 | 0.030 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1996 | 110 | 0.030 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1995 | 73 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 1998 | 358 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2000 | 1234 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 2001 | 3709 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8552 | 0.030 |
Why?
|
| Dactinomycin | 1 | 1995 | 304 | 0.030 |
Why?
|
| Ethanol | 4 | 1974 | 1323 | 0.030 |
Why?
|
| Clinical Trials as Topic | 3 | 2005 | 8055 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1995 | 343 | 0.030 |
Why?
|
| Thromboplastin | 5 | 1979 | 286 | 0.030 |
Why?
|
| Risk Factors | 4 | 2019 | 74333 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2002 | 2316 | 0.030 |
Why?
|
| Health Maintenance Organizations | 1 | 1998 | 660 | 0.030 |
Why?
|
| Kallikreins | 2 | 1996 | 231 | 0.030 |
Why?
|
| Dialysis | 1 | 1995 | 75 | 0.030 |
Why?
|
| Risk | 2 | 2005 | 9632 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 1300 | 0.030 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1998 | 515 | 0.030 |
Why?
|
| Serotonin | 2 | 1971 | 1040 | 0.030 |
Why?
|
| Protein Conformation | 3 | 1998 | 3970 | 0.030 |
Why?
|
| Cell Communication | 1 | 2002 | 1653 | 0.030 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 1995 | 116 | 0.030 |
Why?
|
| Vascular Patency | 2 | 1995 | 901 | 0.030 |
Why?
|
| Male | 26 | 2014 | 359718 | 0.030 |
Why?
|
| Cyclic GMP | 1 | 1995 | 395 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2007 | 3539 | 0.030 |
Why?
|
| Signal Transduction | 1 | 1997 | 23374 | 0.030 |
Why?
|
| Oligopeptides | 2 | 1993 | 1187 | 0.030 |
Why?
|
| Methods | 6 | 1974 | 1074 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 1998 | 613 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 1 | 1994 | 206 | 0.030 |
Why?
|
| Progestins | 1 | 1995 | 302 | 0.030 |
Why?
|
| Chromatography, Affinity | 3 | 1997 | 534 | 0.030 |
Why?
|
| Staphylococcus | 5 | 1976 | 156 | 0.030 |
Why?
|
| Blood Proteins | 1 | 1979 | 1173 | 0.030 |
Why?
|
| Chromatography, Gel | 3 | 1988 | 645 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 10343 | 0.030 |
Why?
|
| Mechlorethamine | 4 | 1976 | 129 | 0.030 |
Why?
|
| Blood Protein Electrophoresis | 4 | 1977 | 71 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1994 | 660 | 0.030 |
Why?
|
| Protein Denaturation | 2 | 1997 | 242 | 0.030 |
Why?
|
| Vena Cava, Inferior | 3 | 1978 | 458 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2005 | 2501 | 0.030 |
Why?
|
| Kringles | 2 | 2002 | 8 | 0.030 |
Why?
|
| Health Policy | 1 | 2005 | 2677 | 0.030 |
Why?
|
| Amides | 1 | 1995 | 448 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2005 | 3258 | 0.020 |
Why?
|
| Cadaver | 1 | 1975 | 1345 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 3725 | 0.020 |
Why?
|
| Thrombocytopenia | 2 | 1976 | 1174 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2001 | 10826 | 0.020 |
Why?
|
| Mathematics | 1 | 1992 | 707 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 1992 | 869 | 0.020 |
Why?
|
| Antithrombins | 1 | 1974 | 313 | 0.020 |
Why?
|
| Depression, Chemical | 3 | 1975 | 185 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 1993 | 641 | 0.020 |
Why?
|
| Chemistry | 2 | 1988 | 348 | 0.020 |
Why?
|
| CHO Cells | 1 | 1993 | 1389 | 0.020 |
Why?
|
| Chemical Phenomena | 2 | 1988 | 508 | 0.020 |
Why?
|
| Adult | 25 | 1998 | 220007 | 0.020 |
Why?
|
| Phenylalanine | 1 | 1991 | 365 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2005 | 4360 | 0.020 |
Why?
|
| Models, Molecular | 2 | 1997 | 5434 | 0.020 |
Why?
|
| Proline | 1 | 1991 | 457 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 2011 | 1316 | 0.020 |
Why?
|
| Glycosylation | 1 | 1992 | 1096 | 0.020 |
Why?
|
| Feedback | 1 | 1993 | 791 | 0.020 |
Why?
|
| Cricetinae | 1 | 1993 | 2427 | 0.020 |
Why?
|
| Veins | 4 | 1998 | 765 | 0.020 |
Why?
|
| Hydroxylamines | 1 | 1988 | 40 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1977 | 1302 | 0.020 |
Why?
|
| Immunosorbent Techniques | 1 | 1988 | 176 | 0.020 |
Why?
|
| Injections, Intravenous | 4 | 1991 | 1385 | 0.020 |
Why?
|
| Middle Aged | 21 | 1998 | 220359 | 0.020 |
Why?
|
| Aged | 18 | 1996 | 169143 | 0.020 |
Why?
|
| Species Specificity | 2 | 2000 | 2418 | 0.020 |
Why?
|
| Hepatic Veins | 2 | 1978 | 112 | 0.020 |
Why?
|
| Acute Disease | 4 | 1987 | 7268 | 0.020 |
Why?
|
| Atrial Fibrillation | 2 | 2005 | 5209 | 0.020 |
Why?
|
| Coronary Angiography | 3 | 1995 | 4563 | 0.020 |
Why?
|
| Ancrod | 1 | 1987 | 7 | 0.020 |
Why?
|
| Crotalid Venoms | 1 | 1987 | 29 | 0.020 |
Why?
|
| Phlebography | 3 | 1980 | 325 | 0.020 |
Why?
|
| Valine | 1 | 1988 | 409 | 0.020 |
Why?
|
| Prothrombin Time | 4 | 1977 | 116 | 0.020 |
Why?
|
| Densitometry | 3 | 1976 | 151 | 0.020 |
Why?
|
| Methionine | 1 | 1988 | 569 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 1996 | 2061 | 0.020 |
Why?
|
| Kaolin | 1 | 1965 | 16 | 0.020 |
Why?
|
| Mammals | 2 | 2002 | 1131 | 0.020 |
Why?
|
| Female | 28 | 1998 | 391246 | 0.020 |
Why?
|
| Edetic Acid | 1 | 1986 | 282 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2005 | 6659 | 0.020 |
Why?
|
| Radionuclide Imaging | 3 | 1973 | 1975 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 1988 | 755 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1987 | 956 | 0.010 |
Why?
|
| Sodium Dodecyl Sulfate | 2 | 1974 | 127 | 0.010 |
Why?
|
| Stimulation, Chemical | 2 | 1994 | 306 | 0.010 |
Why?
|
| Autoradiography | 2 | 1975 | 730 | 0.010 |
Why?
|
| United States | 2 | 2005 | 72448 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 461 | 0.010 |
Why?
|
| Factor IX | 2 | 1979 | 77 | 0.010 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1983 | 80 | 0.010 |
Why?
|
| Thromboxanes | 1 | 1983 | 47 | 0.010 |
Why?
|
| Dextrans | 1 | 1965 | 574 | 0.010 |
Why?
|
| Vascular Diseases | 2 | 1972 | 1181 | 0.010 |
Why?
|
| Random Allocation | 1 | 1988 | 2394 | 0.010 |
Why?
|
| Cardiovascular Diseases | 2 | 1995 | 15760 | 0.010 |
Why?
|
| Up-Regulation | 2 | 2002 | 4122 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1988 | 1617 | 0.010 |
Why?
|
| Extracellular Matrix | 2 | 2006 | 1726 | 0.010 |
Why?
|
| Bronchoconstriction | 1 | 1963 | 139 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 1997 | 14374 | 0.010 |
Why?
|
| Intestines | 1 | 1971 | 1907 | 0.010 |
Why?
|
| Bronchial Diseases | 1 | 1963 | 151 | 0.010 |
Why?
|
| Warfarin | 3 | 1976 | 1518 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1987 | 882 | 0.010 |
Why?
|
| Survival Rate | 1 | 1996 | 12810 | 0.010 |
Why?
|
| Sulfates | 2 | 1973 | 379 | 0.010 |
Why?
|
| RNA, Messenger | 3 | 2002 | 12762 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 1988 | 1577 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 2002 | 429 | 0.010 |
Why?
|
| Heart Massage | 1 | 1961 | 31 | 0.010 |
Why?
|
| Dicumarol | 1 | 1960 | 9 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1994 | 8556 | 0.010 |
Why?
|
| Hemoperitoneum | 1 | 1960 | 38 | 0.010 |
Why?
|
| Corpus Luteum | 1 | 1960 | 81 | 0.010 |
Why?
|
| Recurrence | 1 | 1993 | 8483 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 1142 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 8158 | 0.010 |
Why?
|
| Spleen | 3 | 1974 | 2298 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2002 | 614 | 0.010 |
Why?
|
| Suloctidil | 1 | 1979 | 2 | 0.010 |
Why?
|
| Postoperative Complications | 3 | 1978 | 15679 | 0.010 |
Why?
|
| Hemosiderosis | 1 | 1959 | 66 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2022 | 54306 | 0.010 |
Why?
|
| Ellagic Acid | 1 | 1979 | 5 | 0.010 |
Why?
|
| Factor X | 1 | 1979 | 64 | 0.010 |
Why?
|
| Immunomagnetic Separation | 1 | 1998 | 79 | 0.010 |
Why?
|
| Hepatomegaly | 1 | 1978 | 84 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 2002 | 9185 | 0.010 |
Why?
|
| Blood Viscosity | 1 | 1979 | 124 | 0.010 |
Why?
|
| Radiography | 2 | 1980 | 6965 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 1342 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1998 | 452 | 0.010 |
Why?
|
| Electrodes | 1 | 1980 | 614 | 0.010 |
Why?
|
| Isoleucine | 1 | 1998 | 110 | 0.010 |
Why?
|
| Sequence Tagged Sites | 1 | 1997 | 94 | 0.010 |
Why?
|
| Sodium Chloride | 2 | 1974 | 591 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 1961 | 546 | 0.010 |
Why?
|
| Base Sequence | 1 | 1988 | 12444 | 0.010 |
Why?
|
| Renal Veins | 1 | 1977 | 102 | 0.010 |
Why?
|
| Ischemia | 1 | 2006 | 1893 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1997 | 852 | 0.010 |
Why?
|
| Prothrombin | 2 | 1974 | 191 | 0.010 |
Why?
|
| Infusions, Parenteral | 2 | 1974 | 399 | 0.010 |
Why?
|
| Hematocrit | 2 | 1979 | 629 | 0.010 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1961 | 784 | 0.010 |
Why?
|
| Ascites | 1 | 1978 | 338 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 1976 | 89 | 0.010 |
Why?
|
| Resuscitation | 1 | 1961 | 661 | 0.010 |
Why?
|
| Radiation Effects | 1 | 1976 | 69 | 0.010 |
Why?
|
| Platelet Aggregation | 2 | 1977 | 805 | 0.010 |
Why?
|
| Norpregnenes | 1 | 1995 | 6 | 0.010 |
Why?
|
| Desogestrel | 1 | 1995 | 17 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1978 | 680 | 0.010 |
Why?
|
| Microcirculation | 1 | 1981 | 1278 | 0.010 |
Why?
|
| Infusions, Intravenous | 2 | 1991 | 2235 | 0.010 |
Why?
|
| Plastics | 1 | 1996 | 115 | 0.010 |
Why?
|
| Diabetic Angiopathies | 1 | 1981 | 822 | 0.010 |
Why?
|
| Hypertension | 1 | 1996 | 8595 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1976 | 194 | 0.010 |
Why?
|
| Neuraminidase | 1 | 1976 | 200 | 0.010 |
Why?
|
| Thorium Dioxide | 1 | 1975 | 20 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 1998 | 576 | 0.010 |
Why?
|
| Levonorgestrel | 1 | 1995 | 74 | 0.010 |
Why?
|
| Lipids | 1 | 1987 | 3336 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1982 | 2362 | 0.010 |
Why?
|
| Mononuclear Phagocyte System | 1 | 1975 | 54 | 0.010 |
Why?
|
| Ethinyl Estradiol | 1 | 1995 | 114 | 0.010 |
Why?
|
| Serum Globulins | 1 | 1974 | 24 | 0.010 |
Why?
|
| Liver Cirrhosis | 3 | 1977 | 1931 | 0.010 |
Why?
|
| Chromium Radioisotopes | 1 | 1974 | 34 | 0.010 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 1974 | 44 | 0.010 |
Why?
|
| Rats | 1 | 2011 | 23709 | 0.010 |
Why?
|
| Chemical Fractionation | 1 | 1974 | 62 | 0.010 |
Why?
|
| Cattle | 2 | 1979 | 3847 | 0.010 |
Why?
|
| Wound Healing | 1 | 2006 | 2788 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1998 | 1900 | 0.010 |
Why?
|
| Steroids | 1 | 1959 | 928 | 0.010 |
Why?
|
| Chromogenic Compounds | 1 | 1994 | 31 | 0.010 |
Why?
|
| Clot Retraction | 1 | 1994 | 13 | 0.010 |
Why?
|
| Granulocytes | 1 | 1976 | 551 | 0.010 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1974 | 82 | 0.010 |
Why?
|
| Lung | 4 | 1979 | 9994 | 0.010 |
Why?
|
| Biodegradation, Environmental | 1 | 1974 | 218 | 0.010 |
Why?
|
| Blood Vessels | 2 | 1976 | 1112 | 0.010 |
Why?
|
| Information Systems | 1 | 1996 | 398 | 0.010 |
Why?
|
| Cell Movement | 1 | 2006 | 5206 | 0.010 |
Why?
|
| Protein Folding | 1 | 1997 | 867 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1974 | 573 | 0.010 |
Why?
|
| Gels | 1 | 1974 | 419 | 0.010 |
Why?
|
| Vitamin K | 1 | 1976 | 321 | 0.010 |
Why?
|
| Heart Auscultation | 1 | 1973 | 34 | 0.010 |
Why?
|
| Pregnancy Complications | 2 | 1973 | 2942 | 0.010 |
Why?
|
| Calcium | 1 | 1986 | 5725 | 0.010 |
Why?
|
| Jugular Veins | 1 | 1974 | 211 | 0.010 |
Why?
|
| Plasmids | 1 | 1997 | 2275 | 0.010 |
Why?
|
| Arteriosclerosis Obliterans | 1 | 1971 | 8 | 0.010 |
Why?
|
| Agglutination Tests | 1 | 1971 | 41 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 4169 | 0.010 |
Why?
|
| Kidney Glomerulus | 1 | 1974 | 568 | 0.010 |
Why?
|
| Ligation | 1 | 1973 | 448 | 0.010 |
Why?
|
| Placebos | 1 | 1976 | 1668 | 0.010 |
Why?
|
| Reserpine | 1 | 1971 | 60 | 0.010 |
Why?
|
| Polymyxins | 1 | 1971 | 19 | 0.010 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 1996 | 450 | 0.010 |
Why?
|
| Central Venous Pressure | 1 | 1971 | 79 | 0.010 |
Why?
|
| Indicator Dilution Techniques | 1 | 1971 | 43 | 0.010 |
Why?
|
| Serotonin Antagonists | 2 | 1968 | 144 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1998 | 2651 | 0.010 |
Why?
|
| Blood | 1 | 1974 | 586 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1976 | 1428 | 0.010 |
Why?
|
| Pyridoxine | 1 | 1971 | 108 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1971 | 239 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1976 | 1954 | 0.010 |
Why?
|
| Heart Arrest | 1 | 1961 | 1506 | 0.010 |
Why?
|
| Puerperal Disorders | 1 | 1973 | 300 | 0.010 |
Why?
|
| Mice | 1 | 1997 | 81209 | 0.010 |
Why?
|
| Liver | 3 | 1974 | 7510 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 10442 | 0.010 |
Why?
|
| Angiography | 2 | 1973 | 1605 | 0.010 |
Why?
|
| Extremities | 1 | 1975 | 867 | 0.010 |
Why?
|
| Platelet Adhesiveness | 1 | 1970 | 154 | 0.010 |
Why?
|
| Colorimetry | 1 | 1990 | 153 | 0.010 |
Why?
|
| Shock, Septic | 1 | 1976 | 760 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2000 | 2698 | 0.010 |
Why?
|
| Thrombospondins | 1 | 1990 | 193 | 0.010 |
Why?
|
| Organ Size | 1 | 1974 | 2254 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1959 | 1915 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1979 | 2415 | 0.010 |
Why?
|
| Iproniazid | 1 | 1968 | 8 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 1971 | 554 | 0.010 |
Why?
|
| Iliac Artery | 1 | 1970 | 344 | 0.010 |
Why?
|
| Airway Obstruction | 1 | 1973 | 662 | 0.000 |
Why?
|
| Lipoproteins, IDL | 1 | 1987 | 18 | 0.000 |
Why?
|
| Foot | 1 | 1971 | 573 | 0.000 |
Why?
|
| Mitral Valve | 1 | 1976 | 1486 | 0.000 |
Why?
|
| Arteries | 1 | 1971 | 1126 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1990 | 2262 | 0.000 |
Why?
|
| Enterobacter aerogenes | 1 | 1965 | 2 | 0.000 |
Why?
|
| Lipoproteins, VLDL | 1 | 1987 | 201 | 0.000 |
Why?
|
| Embolization, Therapeutic | 1 | 1976 | 1412 | 0.000 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1976 | 2829 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1991 | 2025 | 0.000 |
Why?
|
| Pregnancy | 4 | 1976 | 29746 | 0.000 |
Why?
|
| Factor XI | 1 | 1965 | 34 | 0.000 |
Why?
|
| Serratia marcescens | 1 | 1965 | 48 | 0.000 |
Why?
|
| Surgical Procedures, Operative | 1 | 1976 | 1913 | 0.000 |
Why?
|
| Shigella | 1 | 1965 | 69 | 0.000 |
Why?
|
| Factor V | 1 | 1965 | 168 | 0.000 |
Why?
|
| Dyspnea | 1 | 1973 | 1353 | 0.000 |
Why?
|
| Epinephrine | 1 | 1968 | 791 | 0.000 |
Why?
|
| Aortic Diseases | 1 | 1970 | 734 | 0.000 |
Why?
|
| Pulmonary Artery | 1 | 1973 | 1921 | 0.000 |
Why?
|
| Salmonella typhi | 1 | 1965 | 199 | 0.000 |
Why?
|
| Sepsis | 1 | 1977 | 2592 | 0.000 |
Why?
|
| Salmonella typhimurium | 1 | 1965 | 344 | 0.000 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1990 | 3802 | 0.000 |
Why?
|
| Oxygen | 1 | 1974 | 4193 | 0.000 |
Why?
|
| Myocardium | 1 | 1974 | 4700 | 0.000 |
Why?
|
| Breast | 1 | 1990 | 1963 | 0.000 |
Why?
|
| Pulse | 2 | 1971 | 218 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1971 | 4902 | 0.000 |
Why?
|
| Thromboangiitis Obliterans | 1 | 1960 | 8 | 0.000 |
Why?
|
| Diabetes Mellitus | 1 | 1979 | 5890 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1973 | 6415 | 0.000 |
Why?
|
| Acute Kidney Injury | 1 | 1971 | 1941 | 0.000 |
Why?
|
| Rupture | 1 | 1960 | 443 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1973 | 12968 | 0.000 |
Why?
|
| Sulfinpyrazone | 1 | 1977 | 15 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 1995 | 22052 | 0.000 |
Why?
|
| Incidence | 1 | 1995 | 21391 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1990 | 11070 | 0.000 |
Why?
|
| Factor VII | 1 | 1956 | 139 | 0.000 |
Why?
|
| Hypertension, Pulmonary | 1 | 1966 | 1570 | 0.000 |
Why?
|
| Risk Assessment | 1 | 1996 | 24102 | 0.000 |
Why?
|
| Bacteriuria | 1 | 1973 | 103 | 0.000 |
Why?
|
| Hemostatics | 1 | 1956 | 243 | 0.000 |
Why?
|
| Thrombophilia | 1 | 1956 | 307 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1968 | 8525 | 0.000 |
Why?
|
| Cohort Studies | 1 | 1995 | 41337 | 0.000 |
Why?
|
| Sex Factors | 1 | 1987 | 10546 | 0.000 |
Why?
|
| Blood Group Antigens | 1 | 1973 | 187 | 0.000 |
Why?
|
| Ischemic Attack, Transient | 1 | 1977 | 899 | 0.000 |
Why?
|
| Diabetes Complications | 1 | 1979 | 1341 | 0.000 |
Why?
|
| ABO Blood-Group System | 1 | 1973 | 369 | 0.000 |
Why?
|
| Lactation | 1 | 1973 | 397 | 0.000 |
Why?
|
| Plethysmography | 1 | 1970 | 174 | 0.000 |
Why?
|
| Oscillometry | 1 | 1970 | 145 | 0.000 |
Why?
|
| Parity | 1 | 1973 | 925 | 0.000 |
Why?
|
| Heart Function Tests | 1 | 1970 | 319 | 0.000 |
Why?
|
| Electrophoresis | 1 | 1970 | 234 | 0.000 |
Why?
|
| Prognosis | 1 | 1970 | 29661 | 0.000 |
Why?
|
| Postpartum Period | 1 | 1956 | 1168 | 0.000 |
Why?
|
| Methysergide | 1 | 1968 | 28 | 0.000 |
Why?
|
| Heart Valve Prosthesis | 1 | 1977 | 1495 | 0.000 |
Why?
|
| Abortion, Spontaneous | 1 | 1973 | 530 | 0.000 |
Why?
|
| Cats | 1 | 1970 | 976 | 0.000 |
Why?
|
| Intermittent Claudication | 1 | 1970 | 305 | 0.000 |
Why?
|
| Coronary Artery Bypass | 1 | 1977 | 2272 | 0.000 |
Why?
|
| Regional Blood Flow | 1 | 1971 | 1490 | 0.000 |
Why?
|
| Neoplasms | 1 | 1976 | 22075 | 0.000 |
Why?
|
| Blood Flow Velocity | 1 | 1971 | 1377 | 0.000 |
Why?
|
| Polymers | 1 | 1974 | 1621 | 0.000 |
Why?
|
| Estrogens | 1 | 1973 | 1520 | 0.000 |
Why?
|
| Delivery, Obstetric | 1 | 1973 | 932 | 0.000 |
Why?
|
| Adolescent | 1 | 1973 | 87809 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1979 | 12427 | 0.000 |
Why?
|
| Movement | 1 | 1971 | 1474 | 0.000 |
Why?
|
| Pre-Eclampsia | 1 | 1973 | 1229 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1990 | 21029 | 0.000 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1973 | 2125 | 0.000 |
Why?
|
| Age Factors | 1 | 1973 | 18413 | 0.000 |
Why?
|
| Smoking | 1 | 1973 | 9073 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1970 | 9288 | 0.000 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1970 | 3763 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 1970 | 39262 | 0.000 |
Why?
|